Allarity Therapeutics earnings release, August 14, 2026

Allarity Therapeutics, Inc. (ALLR) · Form 8-K, Item 2.02 · Filed · SEC filing

Allarity Therapeutics Reports Second

Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

- Completed quarter with $26.9 million in cash and restricted cash

- Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042

- AACR 2026 data linked higher stenoparib

DRP® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP®

-guided patient selection

- Obtained CLIA certification for its in-house laboratory, enabling full control of DRP® testing to accelerate and support U.S. clinical trials

TARPON SPRINGS, Fla.,

AUGUST 14, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30,

2026.

“The second quarter was a highly productive period for Allarity.

During the quarter, the USPTO granted the key U.S. patent covering our stenoparib-specific DRP® companion diagnostic, providing exclusivity to develop stenoparib with its DRP® into April 2042. This establishes a critical, long-term intellectual property foundation for stenoparib development and commercialization and reinforces our confidence in the long-term potential of our approach to pairing anticancer therapeutics with drug-specific companion diagnostics,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics.

“Subsequent to quarter-end, we also successfully completed our manufacturing campaign for stenoparib, securing drug supply in accordance with the more stringent standards required for late-stage clinical development. Completion of this campaign represents an important step as we prepare for a pivotal, registrational trial. We have also secured CLIA certification for our in-house laboratory, enabling us to do all of the necessary testing for the DRP® in-house, which will further secure our ability to control and accelerate the advance of stenoparib toward FDA approval. I am particularly proud of these accomplishments as they position the company to drive stenoparib forward as rapidly as possible. Together with the presentation of our promising, durable Phase 2 clinical benefit data in advanced ovarian cancer patients at leading international oncology conferences, these achievements further strengthen the foundation for accelerating stenoparib toward FDA approval. Finally, I am pleased that we ended the quarter with almost $27 million in cash and restricted cash, providing us with the financial resources to continue the important work of advancing stenoparib.”

Allarity Therapeutics, Inc.

123 E Tarpon Ave

Tarpon

Springs, Florida

U.S.A.

NASDAQ: ALLR

www.allarity.com

Page¹ of 8

Clinical and Drug Development Progress

Allarity Therapeutics, Inc.

123 E Tarpon Ave

Tarpon

Springs, Florida

U.S.A.

NASDAQ: ALLR

www.allarity.com

Page² of 8

Allarity Therapeutics, Inc.

123 E Tarpon Ave

Tarpon

Springs, Florida

U.S.A.

NASDAQ: ALLR

www.allarity.com

Page³ of 8

Corporate and Strategic Developments

Second Quarter 2026 Financial Review

Results of Operations for the Three Months Ended June 30, 2026

Allarity Therapeutics, Inc.

123 E Tarpon Ave

Tarpon

Springs, Florida

U.S.A.

NASDAQ: ALLR

www.allarity.com

Page⁴ of 8

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, especially drug-resistant cancers. By inhibiting PARP and blocking

WNT pathway activation, stenoparib’s therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has completed its first Phase 2 trial for stenoparib in advanced ovarian cancer patients. That trial showed promising and durable clinical benefit in ovarian cancer patients who had two or more lines of prior lines of therapy and recieved stenoparib twice daily. The updated data from this study were presented at the AACR special conference on advances in ovarian cancer in September 2025. These analyses are subject to change as follow-up matures. A new protocol was designed expressly to capitalize on this emerging clinical experience with stenoparib in platinum-resistant patients and began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum- resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval. In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently enrolling patients across multiple VA sites in the U.S.

About the Drug Response Predictor – DRP®

Companion Diagnostic

Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients... (truncated)y treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which Allarity believes may be useful in all cancer types and is patented for dozens of anticancer drugs, has been extensively published in the peer-reviewed literature.

Allarity Therapeutics, Inc.

123 E Tarpon Ave

Tarpon

Springs, Florida

U.S.A.

NASDAQ: ALLR

www.allarity.com

Page⁵ of 8

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in

Denmark and its U.S. business address is in Florida. The Company is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media

LinkedIn: https://www.linkedin.com/company/allaritytx/

Financial statements

Income Statement

Three Months Ended — (in thousands, except for share and per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Revenue:License Revenue$—$—25$—
Revenue:Total revenue25
Operating expenses:Research and development1,3452,3212,6423,724
Operating expenses:General and administrative1,3261,8122,7423,445
Operating expenses:Total operating expenses2,6714,1335,3847,169
Operating expenses:Loss from operations-2,671-4,133-5,359-7,169
Other income (expense):Interest income217237380459
Other income (expense):Interest expense-719-12-948-69
Other income (expense):Foreign exchange gains (losses)-1041,588-1001,726
Other income (expense):Change in fair value of derivative and warrant liabilities-128-1281
Other income (expense):Total other income (expense), net-7341,813-7962,117
Other income (expense):Net loss-3,405-2,320-6,155-5,052
Other income (expense):Net loss per common share, basic and diluted-0.21-0.15-0.39-0.38
Other income (expense):Weighted average common shares outstanding, basic and diluted15,910,72415,543,32115,944,94613,357,266
Other comprehensive lossNet loss-3,405-2,320-6,155-5,052
Other comprehensive lossChange in cumulative translation adjustment-267-1,830-325-2,106
Other comprehensive lossTotal comprehensive loss-3,672-4,150-6,480-7,158

Balance Sheet

December 31, — (in thousands, except for share and per share data)

June 30, – 2026 – (Unaudited)December 31, – 2025
Current assetsCash16,98214,687
Current assetsRestricted Cash9,999
Current assetsOther current assets61265
Current assetsPrepaid expenses3,3772,110
Current assetsTax credit receivable1,310866
Current assetsTotal current assets31,72917,928
Non-current assets:Property, plant and equipment, net386330
Non-current assets:Total assets32,11518,258
Current liabilitiesAccounts payable4,1134,282
Current liabilitiesAccrued expenses and other current liabilities1,9712,667
Current liabilitiesIncome taxes payable8181
Current liabilitiesPromissory note - short term, net of discounts20,862
Current liabilitiesDerivative liability128
Current liabilitiesConvertible promissory notes and accrued interest1,4241,400
Current liabilitiesTotal current liabilities28,5798,430
Current liabilitiesTotal liabilities28,5798,430
Stockholders’ equityCommon stock, $0.0001 par value (250,000,000 shares authorized); 19,124,363 and 19,030,619 shares issued and 15,910,724 and 16,080,980 outstanding at June 30, 2026 and December 31, 2025, respectively33
Stockholders’ equityAdditional paid-in capital144,683144,233
Stockholders’ equityAccumulated other comprehensive loss-1,346-1,021
Stockholders’ equityAccumulated deficit-136,352-130,197
Stockholders’ equityTreasury stock, at cost; 3,213,639 and 2,949,639 shares at June 30, 2026, and December 31, 2025, respectively-3,452-3,190
Stockholders’ equityTotal stockholders’ equity3,5369,828
Stockholders’ equityTotal liabilities and stockholders’ equity32,11518,258
Full release

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipate,” “believe,” “continue,” “could,”

“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,”

“potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the Company’s ongoing and planned clinical development of stenoparib; the enrollment, conduct, timing and potential results of its Phase 2 trials in advanced ovarian cancer and relapsed small cell lung cancer; the potential safety, efficacy, tolerability and clinical benefit of stenoparib; the potential use of the stenoparib DRP® companion diagnostic for patient selection; the advancement of stenoparib toward pivotal development, FDA approval and commercialization; the availability of drug supply from the completed manufacturing campaign; the anticipated benefits of the Company’s CLIA-certified laboratory; the potential commercial use of the DRP® platform and laboratory services; the scope and duration of patent protection for stenoparib and the stenoparib DRP® companion diagnostic; and the Company’s anticipated cash runway and ability to fund its operations and development plans. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to clinical development, patient enrollment, trial execution and regulatory review; the possibility that clinical results may not demonstrate the anticipated safety, efficacy, durability or clinical benefit of stenoparib; the predictive accuracy, validation, regulatory acceptance and clinical utility of the stenoparib DRP® companion diagnostic; the Company’s ability to obtain, maintain and enforce intellectual property protection; the quality, availability and regulatory compliance of stenoparib drug supply; the Company’s ability to maintain its CLIA certification and other required laboratory approvals; the possibility that anticipated efficiencies, cost savings or commercial opportunities may not be realized; reliance on third-party clinical sites, investigators, manufacturers and suppliers; and the Company’s ability to maintain sufficient financial resources and obtain additional funding, if required. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission

(the “SEC”) on March 30, 2026, available at the SEC’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact: investorrelations@allarity.com

Media

Contact:

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390 tsp@carrotize.com

Allarity Therapeutics, Inc.

123 E Tarpon Ave

Tarpon

Springs, Florida

U.S.A.

NASDAQ: ALLR

www.allarity.com

Page⁶ of 8

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.